Cour Pharmaceutical Development Company, Inc.   Report issue

For profit Phase 2
Founded: Northbrook IL United States (2012)

Organization Overview

First Clinical Trial
2018
NCT03486990
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cour Pharmaceutical Development Company, Inc. | COUR Pharmaceutical Development Company, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

cnp-104 (1 trial)

cnp-106 (1 trial)

gliadin (2 trials)

peanut allergen (Palforzia) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4